Precision BioSciences Inc., a clinical stage gene editing company, will be attending the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in New Orleans, Louisiana, from May 13-17, 2025. At the event, they will present five abstracts detailing their _in vivo_ gene editing programs, including data from their lead program PBGENE-HBV for chronic hepatitis B, and partner iECURE's ECUR-506 for OTC deficiency. Additional presentations will cover preclinical results from muscle programs targeting mitochondrial disease and Duchenne Muscular Dystrophy.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。